MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVID‐19 severe respiratory failure (MUST COVID): A retrospective cohort study
BACKGROUND: Few therapies exist to treat severe COVID-19 respiratory failure once it develops. Given known diffuse pulmonary microthrombi on autopsy studies of COVID-19 patients, we hypothesized that tissue plasminogen activator (tPA) may improve pulmonary function in COVID-19 respiratory failure. M...
Main Authors: | Yaffe, Michael, Barrett, Christopher |
---|---|
Other Authors: | Massachusetts Institute of Technology. Department of Biology |
Format: | Article |
Language: | English |
Published: |
Wiley
2023
|
Online Access: | https://hdl.handle.net/1721.1/147027 |
Similar Items
-
STudy of Alteplase for Respiratory failure in SARS‐Cov2/COVID‐19: Study Design of the Phase IIa STARS Trial
by: Moore, Hunter B., et al.
Published: (2020) -
Rescue Therapy for Severe COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) with Tissue Plasminogen Activator (tPA)
by: Barrett, Christopher D
Published: (2020) -
Is there a role for tissue plasminogen activator (tPA) as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome (ARDS)?
by: Barrett, Christopher D., et al.
Published: (2020) -
Tissue plasminogen activator (tPA) treatment for COVID‐19 associated acute respiratory distress syndrome (ARDS): A case series
by: Wang, Janice, et al.
Published: (2020) -
Remdesivir therapy for severe pediatric COVID-19 in Singapore: a single-center retrospective observational cohort study
by: Seah, Valerie Xue Fen, et al.
Published: (2024)